Score Overview
Explore the 2021 public Archive ranking →
Where Inovio Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- INO
2003: 58.0% · 2021: 54.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 1.22 | — |
1 Year2025-09-30 | $ 2.34 | -47.86% |
5 Years2021-09-30 | $ 85.92 | -98.58% |
10 Years2016-09-30 | $ 111.44 | -98.91% |
20 Years2006-09-29 | $ 122.92 | -99.01% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | 20 Years2006-09-29 |
|---|---|---|---|---|---|
| Price | $ 1.22 | $ 2.34 | $ 85.92 | $ 111.44 | $ 122.92 |
| Return | — | -47.86% | -98.58% | -98.91% | -99.01% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | -$ 65.34K | -$ 6.07B | $ 36.67B |
| 2025 | $ 65.34K | -$ 84M | $ 58M |
| 2024 | $ 217.76K | -$ 107M | $ 94M |
| 2023 | $ 832.01K | -$ 135M | $ 145M |
| 2022 | $ 10M | -$ 279M | $ 252M |
| 2021 | $ 1M | -$ 303M | $ 401M |
| 2020 | $ 7M | -$ 166M | $ 411M |
| 2019 | $ 4M | -$ 119M | $ 89M |
| 2018 | $ 30M | -$ 96M | $ 81M |
| 2017 | $ 42M | -$ 88M | $ 127M |
| 2016 | $ 35M | -$ 73M | $ 104M |
| 2015 | $ 40M | -$ 29M | $ 162M |
| 2014 | $ 10M | -$ 36M | $ 93M |
| 2013 | $ 13M | -$ 66M | $ 52M |
| 2012 | $ 4M | -$ 19M | $ 13M |
| 2011 | $ 9M | -$ 15M | $ 30M |
| 2010 | $ 6M | -$ 17M | $ 21M |
| 2009 | $ 9M | -$ 24M | $ 43M |
| 2008 | $ 2M | -$ 12M | $ 14M |
| 2007 | $ 4M | -$ 11M | $ 27M |
| 2006 | $ 3M | -$ 12M | $ 23M |
| 2005 | $ 5M | -$ 15M | $ 17M |
| 2004 | $ 1M | -$ 10M | $ 17M |
| 2003 | $ 80.53K | -$ 4M | $ 13M |
| 2002 | $ 189.52K | -$ 5M | $ 875.44K |
| 2001 | $ 4M | -$ 8M | $ 1M |
| 2000 | $ 5M | -$ 9M | $ 6M |
| 1999 | $ 8M | -$ 6M | $ 9M |
| IPO1998 | $ 8M | -$ 6M | $ 6M |
Inovio Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 7M to $ 65.34K and net income went from -$ 166M to -$ 84M. Revenue increased in 1 of those 5 years; net income in 4.
Between 2015 and 2025, revenue declined from $ 40M to $ 65.34K and net income went from -$ 29M to -$ 84M. Revenue increased in 3 of those 10 years; net income in 4.
Inovio Pharmaceuticals Inc currently holds a 20-year HDB Score of 1.8 out of 10. How the HDB Score is calculated.
Membership
Continue INO’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
